Akebia Therapeutics Analyst Ratings
Akebia Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 220.51% | HC Wainwright & Co. | → $3.75 | Reiterates | Buy → Buy |
| 08/28/2023 | 220.51% | HC Wainwright & Co. | $2 → $3.75 | Upgrades | Neutral → Buy |
| 08/11/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/21/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/14/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/02/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/31/2023 | 241.88% | Piper Sandler | $2 → $4 | Upgrades | Neutral → Overweight |
| 05/30/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/26/2023 | 70.94% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/09/2023 | 70.94% | Needham | → $2 | Reiterates | → Neutral |
| 04/26/2023 | 70.94% | HC Wainwright & Co. | $1.25 → $2 | Maintains | Neutral |
| 03/31/2023 | 6.84% | HC Wainwright & Co. | → $1.25 | Reiterates | → Neutral |
| 03/10/2023 | 6.84% | HC Wainwright & Co. | → $1.25 | Reiterates | → Neutral |
| 02/22/2023 | 6.84% | HC Wainwright & Co. | → $1.25 | Maintains | Neutral |
| 05/16/2022 | 6.84% | HC Wainwright & Co. | $2 → $1.25 | Maintains | Neutral |
| 03/31/2022 | 70.94% | HC Wainwright & Co. | $10 → $2 | Downgrades | Buy → Neutral |
| 03/31/2022 | — | Needham | Downgrades | Buy → Hold | |
| 03/31/2022 | 70.94% | Mizuho | $6 → $2 | Downgrades | Buy → Neutral |
| 03/31/2022 | 70.94% | Piper Sandler | $8 → $2 | Downgrades | Overweight → Neutral |
| 11/11/2021 | 754.7% | HC Wainwright & Co. | $6 → $10 | Maintains | Buy |
| 03/08/2021 | 583.76% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 412.82% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 01/29/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 10/26/2020 | 669.23% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 09/04/2020 | 156.41% | Morgan Stanley | $12 → $3 | Maintains | Equal-Weight |
| 09/04/2020 | 412.82% | BTIG | $26 → $6 | Maintains | Buy |
| 09/04/2020 | 754.7% | HC Wainwright & Co. | $17 → $10 | Maintains | Buy |
| 07/15/2020 | 925.64% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
| 05/06/2020 | 1438.46% | JP Morgan | $13 → $18 | Maintains | Overweight |
| 05/06/2020 | 840.17% | Morgan Stanley | $9 → $11 | Maintains | Equal-Weight |
| 05/06/2020 | 1352.99% | HC Wainwright & Co. | $16 → $17 | Maintains | Buy |
| 05/06/2020 | 1352.99% | Mizuho | $15 → $17 | Maintains | Buy |
| 05/05/2020 | 1438.46% | Needham | $15 → $18 | Maintains | Buy |
| 03/11/2020 | 1182.05% | Mizuho | $16 → $15 | Reiterates | → Buy |
| 02/20/2020 | 1011.11% | JP Morgan | $10 → $13 | Maintains | Overweight |
| 11/18/2019 | 1267.52% | HC Wainwright & Co. | $17 → $16 | Maintains | Buy |
| 08/06/2019 | 1352.99% | HC Wainwright & Co. | $19 → $17 | Maintains | Buy |
| 05/02/2019 | — | JP Morgan | Initiates Coverage On | → Overweight | |
| 03/20/2019 | 669.23% | Citigroup | → $9 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/27/2023 | 220.51% | HC Wainwright公司 | →$3.75 | 重申 | 購買→購買 |
| 2023年08月28日 | 220.51% | HC Wainwright公司 | $2→$3.75 | 升級 | 中性→購買 |
| 2023年08月11日 | 70.94% | HC Wainwright公司 | →$2 | 重申 | 中性→中性 |
| 2023年6月21日 | 70.94% | HC Wainwright公司 | →$2 | 重申 | 中性→中性 |
| 2023/06/14 | 70.94% | HC Wainwright公司 | →$2 | 重申 | 中性→中性 |
| 06/02/2023 | 70.94% | HC Wainwright公司 | →$2 | 重申 | 中性→中性 |
| 2023年05月31日 | 241.88% | 派珀·桑德勒 | $2→$4 | 升級 | 中性→超重 |
| 2023年05月30日 | 70.94% | HC Wainwright公司 | →$2 | 重申 | 中性→中性 |
| 2023年05月26日 | 70.94% | HC Wainwright公司 | →$2 | 重申 | 中性→中性 |
| 05/09/2023 | 70.94% | 李約瑟 | →$2 | 重申 | →中性 |
| 04/26/2023 | 70.94% | HC Wainwright公司 | $1.25→$2 | 維護 | 中性 |
| 03/31/2023 | 6.84% | HC Wainwright公司 | →$1.25 | 重申 | →中性 |
| 03/10/2023 | 6.84% | HC Wainwright公司 | →$1.25 | 重申 | →中性 |
| 02/22/2023 | 6.84% | HC Wainwright公司 | →$1.25 | 維護 | 中性 |
| 05/16/2022 | 6.84% | HC Wainwright公司 | $2→$1.25 | 維護 | 中性 |
| 03/31/2022 | 70.94% | HC Wainwright公司 | $10→$2 | 評級下調 | 購買→中性 |
| 03/31/2022 | - | 李約瑟 | 評級下調 | 購買→Hold | |
| 03/31/2022 | 70.94% | 瑞穗 | $6→$2 | 評級下調 | 購買→中性 |
| 03/31/2022 | 70.94% | 派珀·桑德勒 | $8→$2 | 評級下調 | 超重→中性 |
| 2021年11月11日 | 754.7% | HC Wainwright公司 | $6→$10 | 維護 | 買 |
| 03/08/2021 | 583.76% | 康託·菲茨傑拉德 | →$8 | 開始承保 | →超重 |
| 03/08/2021 | 412.82% | HC Wainwright公司 | $9→$6 | 維護 | 買 |
| 2021/01/29 | - | 摩根大通 | 評級下調 | 中性→減持 | |
| 10/26/2020 | 669.23% | HC Wainwright公司 | $10→$9 | 維護 | 買 |
| 09/04/2020 | 156.41% | 摩根士丹利 | $12→$3 | 維護 | 等重 |
| 09/04/2020 | 412.82% | BTIG | $26→$6 | 維護 | 買 |
| 09/04/2020 | 754.7% | HC Wainwright公司 | $17→$10 | 維護 | 買 |
| 07/15/2020 | 925.64% | 摩根士丹利 | $11→$12 | 維護 | 等重 |
| 05/06/2020 | 1438.46% | 摩根大通 | $13→$18 | 維護 | 超重 |
| 05/06/2020 | 840.17% | 摩根士丹利 | $9→$11 | 維護 | 等重 |
| 05/06/2020 | 1352.99% | HC Wainwright公司 | $16→$17 | 維護 | 買 |
| 05/06/2020 | 1352.99% | 瑞穗 | $15→$17 | 維護 | 買 |
| 05/05/2020 | 1438.46% | 李約瑟 | $15→$18 | 維護 | 買 |
| 03/11/2020 | 1182.05% | 瑞穗 | $16→$15 | 重申 | →購買 |
| 02/20/2020 | 1011.11% | 摩根大通 | $10→$13 | 維護 | 超重 |
| 2019年11月18日 | 1267.52% | HC Wainwright公司 | $17→$16 | 維護 | 買 |
| 2019年08月06日 | 1352.99% | HC Wainwright公司 | $19→$17 | 維護 | 買 |
| 2019年05月02日 | - | 摩根大通 | 開始承保 | →超重 | |
| 2019/03/20 | 669.23% | 花旗集團 | →$9 | 開始承保 | →中性 |
What is the target price for Akebia Therapeutics (AKBA)?
木通治療公司(AKBA)的目標價格是多少？
The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by HC Wainwright & Co. on September 27, 2023. The analyst firm set a price target for $3.75 expecting AKBA to rise to within 12 months (a possible 220.51% upside). 14 analyst firms have reported ratings in the last year.
木通治療公司(納斯達克代碼：AKBA)的最新目標價是由HC Wainwright&Co.於2023年9月27日報道的。這家分析公司將目標價定為3.75億美元，預計AKBA將在12個月內上漲(可能上漲220.51)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for Akebia Therapeutics (AKBA)?
木通治療公司(AKBA)的最新分析師評級是多少？
The latest analyst rating for Akebia Therapeutics (NASDAQ: AKBA) was provided by HC Wainwright & Co., and Akebia Therapeutics reiterated their buy rating.
木通治療公司(納斯達克代碼：AKBA)的最新分析師評級是由HC Wainwright&Co.提供的，木通治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Akebia Therapeutics (AKBA)?
木通治療公司(AKBA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akebia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akebia Therapeutics was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與木通治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。木通治療公司的上一次評級是在2023年9月27日提交的，所以你應該預計下一次評級將在2024年9月27日左右的某個時候提供。
Is the Analyst Rating Akebia Therapeutics (AKBA) correct?
分析師對木通治療公司(AKBA)的評級正確嗎？
While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a reiterated with a price target of $0.00 to $3.75. The current price Akebia Therapeutics (AKBA) is trading at is $1.17, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的木通治療(AKBA)評級被重申，目標價在0.00美元至3.75美元之間。木通治療公司(AKBA)目前的交易價格為1.17美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。